Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma

被引：0
|
作者：
Albrecht, L. J. [1 ]
Dimitriou, F. [2 ]
Grover, P. [3 ]
Hassel, J. C. [4 ,5 ]
Erdmann, M. [6 ]
Forschner, A. [7 ]
Johnson, D. [8 ,9 ]
Livingstone, E. [1 ]
Roesch, A. [1 ,10 ]
Ugurel, S. [1 ]
Schulz, C. [4 ,5 ]
Berking, C. [6 ]
Menzies, A. M. [3 ,11 ,12 ]
Long, G. V. [11 ,12 ]
Dummer, R. [2 ]
Schadendorf, D. [1 ,10 ]
Zimmer, L. [1 ]
机构：
[1] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[2] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland
[3] Univ Sydney, Melanoma Inst Australia, Sydney, Australia
[4] Univ Hosp Heidelberg, Dept Dermatol, Heidelberg, Germany
[5] Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[6] Univ Hosp Erlangen, Dept Dermatol, Erlangen, Germany
[7] Univ Hosp Tuebingen, Dept Dermatol, Tubingen, Germany
[8] VUMC, Dept Med, Div Hematol & Oncol, Nashville, TN USA
[9] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA
[10] German Canc Consortium DKTK, Essen, Germany
[11] Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, Australia
[12] Univ Sydney, Fac Med & Hlth, Sydney, Australia
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
eP023
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [21] VEDOLIZUMAB PLUS ANTI-PD1 ANTIBODY IN ADVANCED MELANOMA PATIENTS WITH INFLAMMATORY ENTEROCOLITIS
    Javed, Asad
    Freesmeier, Michele
    Zakharia, Yousef
    Milhem, Mohammed
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1313 - A1313
  • [22] Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
    Placzke, Joanna
    Rosinska, Magdalena
    Sobczuk, Pawel
    Zietek, Marcin
    Kempa-Kaminska, Natasza
    Cybulska-Stopa, Bozena
    Kaminska-Winciorek, Grazyna
    Bal, Wieslaw
    Mackiewicz, Jacek
    Galus, Lukasz
    Las-Jankowska, Manuela
    Jankowski, Michal
    Dziura, Robert
    Drucis, Kamil
    Borkowska, Aneta
    Switaj, Tomasz
    Rogala, Pawel
    Kozak, Katarzyna
    Klimczak, Anna
    Jagodzinska-Mucha, Paulina
    Szumera-Cieckiewicz, Anna
    Kosela-Paterczyk, Hanna
    Rutkowski, Piotr
    CANCERS, 2023, 15 (17)
  • [23] Adjuvant Therapy with anti-PD1 Antibodies and Braf/Mek Inhibitors for malignant Melanoma in Stage III - a monocentric Analysis of the Skin Cancer Center Rhein-Main
    Nikfarjam, U.
    Dudda, M.
    Moussa, R.
    Pawlowski, J.
    Mitzel-Rink, H.
    Grabbe, S.
    Loquai, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 81 - 81
  • [24] Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors.
    Barcena, Edelyn
    VanAnh Trinh
    McIntyre, Susan E.
    Simien, Rinata
    Cain, Suzanne
    Diab, Adi
    Amaria, Rodabe Navroze
    Patel, Sapna Pradyuman
    Glitza, Isabella Claudia
    Tawbi, Hussein Abdul-Hassan
    Davies, Michael A.
    Hwu, Wen-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] ANTI-PD1 THERAPY IN PATIENTS WITH METASTATIC MELANOMA: A SINGLE CENTRE EXPERIENCE
    Nguyen, B.
    Robinson, E.
    Arora, A.
    Sayed, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 65 - 65
  • [26] Predicting the response to anti-PD1 therapy in metastatic melanoma
    Heinzerling, Lucie
    Kirchberger, Michael Constantin
    Walter, Lisa
    Schuler, Gerold
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S576 - S579
  • [27] Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have received PD-1 based therapy
    Saab, Karim
    Mooradian, Meghan
    Wang, Daniel Ying
    Chon, Jeewon
    Xia, Cathy Yi
    Bialczak, Angelica
    Abbate, Kelly
    Menzies, Alexander M.
    Johnson, Douglas Buckner
    Sullivan, Ryan J.
    Shoushtari, Alexander Noor
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
    Brown, Lauren J.
    Weppler, Alison
    Bhave, Prachi
    Allayous, Clara
    Patrinely, J. Randall, Jr.
    Ott, Patrick
    Sandhu, Shahneen
    Haydon, Andrew
    Lebbe, Celeste
    Johnson, Douglas B.
    Long, Georgina V.
    Menzies, Alexander A.
    Carlino, Matteo S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (05)
  • [29] Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
    Jackson, Natalie
    Rodgers, Theresa
    John, Ida
    Milton, Denai R.
    Haydu, Lauren Elaine
    Amaria, Rodabe Navroze
    Diab, Adi
    McQuade, Jennifer Leigh
    Patel, Sapna Pradyuman
    Tawbi, Hussein Abdul-Hassan
    Wong, Michael K. K.
    Davies, Michael A.
    Glitza, Isabella Claudia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] "Interchangeability" of anti-PD1 antibodies in patients (pts) with metastatic melanoma (mM)
    Kravchuk, Darya
    Fedyanin, Mikhail
    Rays, Anastasia
    Moiseenko, Fedor Vladimirovich
    Ivanilov, Kirill
    Popov, Vladimir
    Glazkova, Elena
    Chubenko, Viacheslav
    Levchenko, Evgeny
    Volkov, Nikita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345